You are here

Article Text

Article menu

Download PDFPDF

Ovarian Cancer
Ovarian Carcinosarcomas Associated With Prolonged Use of Tamoxifen: Case Reports
  1. Ofer Lavie, MD*,
  2. Teri Longacre, MD†,
  3. Yakir Segev, MD, MSc* and
  4. Amreen Husain, MD‡
  1. * Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Carmel Medical Center, Haifa, Israel; and
  2. † Department of Pathology, and
  3. ‡ Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Stanford University School of Medicine, Stanford, CA.
  1. Address correspondence and reprint requests to Yakir Segev, MD, MSc, Department of Obstetrics and Gynecology, Carmel Medical Center, 7 Michal St, Haifa, Israel. E-mail: segevyakir{at}yahoo.com.

Abstract

Background: Recent studies have indicated that the risk associated with tamoxifen may be substantially higher for uterine malignant mixed müllerian tumors and uterine sarcomas.

Case: We present 2 cases of ovarian carcinosarcomas in patients with a personal history of breast carcinoma who were treated for a prolonged period with tamoxifen.

Conclusions: To our knowledge, these 2 cases are the first to describe the possible association between ovarian carcinosarcomas and previous personal and familial history of breast carcinoma and\or prolonged use of tamoxifen. These cases may suggest that like in the uterus, tamoxifen has a possible delayed effect, which might be responsible for the formation of aggressive tumors of unclear pathogenesis in the ovaries.

  • Ovarian carcinosarcoma
  • Tamoxifen
  • Breast carcinoma

https://doi.org/10.1111/IGC.0b013e3181a83fbf

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.